WallStreetZenWallStreetZen

NASDAQ: CRNX
Crinetics Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CRNX past revenue growth

How has CRNX's revenue growth performed historically?
Company
-15.28%
Industry
148.64%
Market
17.33%
CRNX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CRNX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CRNX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CRNX earnings and revenue history

Current Revenue
$4.0M
Current Earnings
-$214.5M
Current Profit Margin
-5,345.9%

CRNX Return on Equity

Current Company
-52.9%
Current Industry
-63.5%
Current Market
188%
CRNX's Return on Equity (-52.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CRNX announces earnings.

CRNX Return on Assets

Current Company
-45.5%
Current Industry
2.9%
CRNX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CRNX Return on Capital Employed

Current Company
-36.27%
Current Industry
19.5%
CRNX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CRNX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CRNX$4.01M-$212.22M-$214.53M+10.57%N/A
XENE$0.00-$179.14M-$182.39M-100.00%N/A
FOLD$399.36M-$92.08M-$151.58M+34.35%N/A
ARWR$181.74M-$262.45M-$296.81M+30.90%N/A
BHVN$0.00-$402.64M-$408.17MN/AN/A
View Top Biotech Stocks

CRNX earnings dates

Next earnings date
May 2, 2024

Crinetics Pharmaceuticals Earnings & Revenue FAQ

What were CRNX's earnings last quarter?

On Invalid Date, Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 2023 earnings per share (EPS) of -$0.88, up 6.02% year over year. Total Crinetics Pharmaceuticals earnings for the quarter were -$60.10 million. In the same quarter last year, Crinetics Pharmaceuticals's earnings per share (EPS) was -$0.83.

If you're new to stock investing, here's how to buy Crinetics Pharmaceuticals stock.

What was CRNX's earnings growth in the past year?

As of Q2 2024, Crinetics Pharmaceuticals's earnings has grown year over year. Crinetics Pharmaceuticals's earnings in the past year totalled -$214.53 million.

What is CRNX's earnings date?

Crinetics Pharmaceuticals's earnings date is Invalid Date. Add CRNX to your watchlist to be reminded of CRNX's next earnings announcement.

What was CRNX's revenue last quarter?

On Invalid Date, Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 2023 revenue of $0.00 up 100% year over year. In the same quarter last year, Crinetics Pharmaceuticals's revenue was $709.00 thousand.

What was CRNX's revenue growth in the past year?

As of Q2 2024, Crinetics Pharmaceuticals's revenue has grown -15.28% year over year. This is 163.92 percentage points lower than the US Biotechnology industry revenue growth rate of 148.64%. Crinetics Pharmaceuticals's revenue in the past year totalled $4.01 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.